Stock Ratings / Health Care / ODTX / insiders

PRME (31) MGTX (21) GLUE (27) CGEM (32) ⌘ Pro Terminal →

Odyssey Therapeutics Inc. (ODTX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$19.54 -1.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $19.45

Odyssey Therapeutics Inc. (ODTX) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $953.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ODTX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ODTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Odyssey Therapeutics Inc. (NASDAQ: ODTX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $19.54 (-1.46% 1D, market cap $953.0M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ODTX ranks #269 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ODTX compare to PRME and MGTX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ODTX carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PRME (Prime Medicine Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $950.4M) and MGTX (MeiraGTx Holdings plc) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $932.1M). Among the 5-stock peer group, ODTX leads on earnings multiple (N/A) while PRME leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ODTX?

▼

Per ODTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001882782), Odyssey Therapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $269.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $19.45 (-0.45%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY • 50.1% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-2.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ODTX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (52/100 Composite)

🔍 WHY ODTX SCORES 52/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (25% of score)

FRED Regime × Technicals: 32% of 52W Range • RSI-14 at 50.8 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$18.26-0.9% Next Q

Q2 (-2Q)

Grade D$18.10+6.6% Next Q

Q3 (-1Q)

Grade D$19.30+1.2% Next Q

Current

Grade D+$19.54-1.1% Hist 90D α

Trajectory: D (44) → D+ (52)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ODTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ODTX currently carries a cautious 52/100 (D+) rating due to Whale & Options Positioning (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($21.66) and Max Pain ($20.52) forces dealer call-delta covering toward $30.50.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ODTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ODTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 52%NO 48%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

ODTX Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ODTX)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ODTX. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ODTX)

✓Walkthrough of ODTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ODTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +19.00%▲ ASCENDING CHANNEL

2026-11-02O $19.54H $19.83L $19.54C $19.54VOL 212.8K

RES: $34.95SUP: $16.58SMA50: $21.66SMA200: $19.72

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ODTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ODTX Butterfly Map → + Track ODTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ODTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ODTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ODTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ODTX)

Health Care Rank #269 of 1016 ⚔️ PRME vs ODTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ODTX vs. PRME, MGTX, GLUE, CGEM)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Odyssey Therapeutics Inc. (ODTX) ranks #269 by composite RQD confidence (52/100, grade D+) and #365 by equity capitalization ($953.0M). Within this direct 5-issuer industry benchmark cohort, ODTX leads on earnings valuation at N/A trailing P/E, while PRME leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ODTX currently leads its immediate peer cohort in composite quantitative strength at 52/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ODTX ACTIVE Odyssey Therapeutics Inc.	D+	52/100	—	—	—	-1.46%	$953.0M	Benchmark Subject
PRME Prime Medicine Inc.	E	31/100	—	—	-35.0%	-9.92%	$950.4M	/prme-vs-odtx →
MGTX MeiraGTx Holdings plc	E	21/100	—	—	-35.0%	-2.21%	$932.1M	/mgtx-vs-odtx →
GLUE Monte Rosa Therapeutics Inc.	E	27/100	—	—	-35.0%	-1.01%	$927.4M	/glue-vs-odtx →
CGEM Cullinan Therapeutics Inc.	E	32/100	—	—	-35.0%	-2.72%	$994.3M	/cgem-vs-odtx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001882782

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Odyssey Therapeutics Inc. (ODTX) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, ODTX closed FY2025 with $269.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$269.8M	—

3. ODTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ODTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ODTX compare to PRME and MGTX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ODTX?

Where is ODTX trading relative to its 50-day, 200-day, and 52-week technical levels?

ODTX last traded at $19.54 (-1.46% on volume of 166,402 shares), positioning the stock -9.79% below its 50-day simple moving average ($21.66) and -0.91% below its 200-day simple moving average ($19.72). Across its 52-week range of $15.10 to $29.05, ODTX sits at the 31.8% percentile with a 14-day RSI of 50.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($17.10 to $21.98).

ODTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are ODTX insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies ODTX leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: ODTX RQD Cockpit ODTX 12M Forecast ODTX Earnings & Move ODTX Dividends & DRIP ODTX Insiders & 13F ODTX Whale Options ODTX Profit Sankey ODTX News & Why

ROARABLE RATING BRIEF • RQD 52/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ODTX — Odyssey Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:14:25Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ODTX scores 52 out of 100, a letter grade of D+ with the verdict label "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:

Fundamental cash engine: 10 / 20. The rating reflects ROIC of 0% and FCF yield of 0%. For a prospective investor, this means the source data shows no measurable return on invested capital and no free-cash generation to support the valuation from operations.
Whale 13F flow: 7 / 20. This pillar reflects institutional accumulation and options positioning. The source data does not include 13F holder detail (see Analyst View), so this score is a rating output without underlying holder figures in the provided material.
Insider conviction: 9 / 20. This pillar reflects SEC Form 4 and Congressional PTR cluster flow. No insider transaction records are present in the holders section, so the score cannot be traced to specific trades here.
Macro regime fit: 13 / 20. Per the rating, beta is 1.0 and the score reflects sector sensitivity, meaning the stock is rated as moving in line with the broader market rather than offering a defensive or differentiated beta profile.
Forensic balance sheet: 13 / 20. Per the rating, Altman Z is 2.5, Piotroski F is 6/9, and Debt/Equity is 0.5. This is the strongest pillar and suggests a moderately sound balance sheet relative to the weak cash-generation picture.

Taken together, the rating points to a valuation supported more by balance-sheet resilience and market narrative than by current cash earnings. The upside driver a prospective investor would weigh is the balance-sheet pillar and the news flow; the valuation tradeoff is that the 10/20 cash-engine score leaves no earnings base to anchor price targets. The rating's verdict is a trim signal, not a recommendation to act.

Business

Per the SEC financials and profile, Odyssey Therapeutics Inc. (ODTX) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. The profile reports a market capitalization of $1.0B. Per the news wire, the company's disclosed development activity centers on OD-001 in ulcerative colitis, with Phase 2a data and presentations referenced. Revenue is reported as $0.0M, so the source data does not show a commercial product revenue stream. Customers and monetization model are not available in source data.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025 (filed 2025-12-31)	$0.0M	$0.0M	$0.0M	N/A	N/A	$41.7M	N/A

Per the SEC financials, FY 2025 reports zero revenue, zero operating income, and zero net income, with cash of $41.7M. Gross, operating, and net margins are each 0% per the market data, and ROIC is 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 6/9, with Debt/Equity of 0.5. The balance sheet therefore appears less stretched than the income statement would suggest, though debt in dollar terms is not available in source data.

Recent Catalysts & News Wire Analysis

Per the recent news wire, all six items are tagged YELLOW with impact label MARKET WIRE, relating to ODTX:

An oral presentation of additional Phase 2a induction data for OD-001 in ulcerative colitis at UEG Week 2026.
A Phase 2a study design presentation evaluating OD-001 combined with vedolizumab at ACG 2026.
A report characterizing Phase 2a ulcerative colitis data for oral OD-001 as positive and supporting further development.
Analyst-target and stock-forecast coverage from third-party aggregators.

Risk watch items: the news wire covers clinical-stage data and presentations, while the financials show no revenue. Proprietary signals in the Butterfly graph: none. Per the Butterfly Supply-Chain Graph, no supply-chain links are recorded.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, supply chain is "NONE" and butterfly links are empty, so upstream and downstream dependencies cannot be mapped from source data. Sector correlation is limited to the Health Care / Biological Products classification and beta of 1.0. Second-order bottlenecks to watch are not identifiable from the provided sources; clinical-readout timing tied to the OD-001 program is the principal catalyst thread in the news wire.

Open Questions

What is the company's cash burn rate and runway given $41.7M in cash and zero revenue?
What is the debt balance in dollar terms, given Debt/Equity of 0.5 but debt reported as N/A?
What are the underlying holder and insider records behind the 13F and Form 4 pillar scores of 7/20 and 9/20?
What are the milestone timelines and clinical-readout dates for OD-001?
What are the P/E, EPS, and EV/EBITDA figures, which the source data does not provide given the absence of earnings?

ODTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Odyssey Therapeutics Inc. (ODTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ODTX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 16h ago

Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026

Yahoo Finance report covering Odyssey Therapeutics Inc. (ODTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 19h ago

Odyssey Therapeutics (Nasdaq:ODTX) - Stock Analysis

Simply Wall St report covering Odyssey Therapeutics Inc. (ODTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 22h ago

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Stock Has Consensus Target Price of $35.75 According to Brokerages

MarketBeat report covering Odyssey Therapeutics Inc. (ODTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026

Yahoo Finance report covering Odyssey Therapeutics Inc. (ODTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Quiver Quantitative • 1d ago

Odyssey Therapeutics Reports Positive Phase 2a Ulcerative Colitis Data for Oral OD-001, Supporting Further Development

Quiver Quantitative report covering Odyssey Therapeutics Inc. (ODTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Odyssey Therapeutics (NasdaqCM:ODTX) Stock Forecast & Analyst Predictions

Simply Wall St report covering Odyssey Therapeutics Inc. (ODTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST MarketBeat • 1d ago

Odyssey Therapeutics (NASDAQ:ODTX) Upgraded at UBS Group

MarketBeat report covering Odyssey Therapeutics Inc. (ODTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 8d ago

Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts

Odyssey Therapeutics (NASDAQ:ODTX) presented additional data from its open-label Phase IIa trial of OD-001, an oral RIPK2 scaffolding inhibitor for moderate-to-severe ulcerative colitis, during its UEG Week 2026 investor

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ODTX Bull vs. Bear Conversation Board — What's Your Call at $19.54?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ODTX 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $21.42 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ODTX (D+ • RQD 52/100) a Buy at $19.83?

Welcome to the ODTX (Odyssey Therapeutics Inc.) Roar Pit. Current RQD Composite is 52/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $16.06 (-19.0%)

Spot @ $19.83

Pump the brakes on ODTX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ODTX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Odyssey Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $23.20 (+17.0%)

Spot @ $19.83

ODTX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ODTX, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $19.83 (52-wk range $15.10 - $29.05), any beat on forward guidance forces shorts and underweight funds to chase.